LBC
NVO

Lowe Brockenbrough & Co’s Novo Nordisk NVO Stock Holding History

Lowe Brockenbrough & Co’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29M Hold
26,886
– – 0.06% 168
2026
Q1 		$988K Sell
26,886
-2,130
-7% -$101K 0.05% 178
2025
Q4 		$1.48M Sell
29,016
-1,609
-5% -$82.3K 0.07% 152
2025
Q3 		$1.7M Sell
30,625
-176
-0.6% -$10.3K 0.09% 135
2025
Q2 		$2.13M Sell
30,801
-450
-1% -$30.6K 0.12% 122
2025
Q1 		$2.21M Buy
+31,251
New +$2.58M 0.15% 118
2024
Q4 		– Sell
-32,782
Closed -$3.9M – 266
2024
Q3 		$3.9M Sell
32,782
-468
-1% -$62.4K 0.25% 93
2024
Q2 		$4.75M Sell
33,250
-1,130
-3% -$150K 0.32% 79
2024
Q1 		$4.45M Sell
34,380
-3,216
-9% -$383K 0.3% 87
2023
Q4 		$3.89M Buy
37,596
+1,543
+4% +$153K 0.3% 87
2023
Q3 		$3.28M Sell
36,053
-1,559
-4% -$137K 0.25% 99
2023
Q2 		$3.04M Sell
37,612
-198
-0.5% -$16.2K 0.23% 99
2023
Q1 		$3.03M Sell
37,810
-360
-0.9% -$25.5K 0.25% 97
2022
Q4 		$2.58M Sell
38,170
-772
-2% -$45.3K 0.22% 102
2022
Q3 		$1.94M Sell
38,942
-462
-1% -$24.7K 0.19% 122
2022
Q2 		$2.19M Sell
39,404
-3,770
-9% -$209K 0.19% 116
2022
Q1 		$2.42M Sell
43,174
-1,220
-3% -$62.6K 0.18% 118
2021
Q4 		$2.49M Sell
44,394
-1,000
-2% -$54.2K 0.18% 109
2021
Q3 		$2.18M Buy
45,394
+140
+0.3% +$6.77K 0.17% 124
2021
Q2 		$1.9M Buy
45,254
+178
+0.4% +$6.9K 0.17% 114
2021
Q1 		$1.52M Sell
45,076
-300
-0.7% -$10.7K 0.15% 127
2020
Q4 		$1.58M Sell
45,376
-1,410
-3% -$48.7K 0.17% 116
2020
Q3 		$1.62M Sell
46,786
-400
-0.8% -$13.3K 0.2% 109
2020
Q2 		$1.54M Sell
47,186
-1,500
-3% -$47.9K 0.21% 108
2020
Q1 		$1.47M Sell
48,686
-650
-1% -$19.4K 0.24% 100
2019
Q4 		$1.43M Hold
49,336
– – 0.18% 124
2019
Q3 		$1.27M Buy
49,336
+1,750
+4% +$44.3K 0.17% 128
2019
Q2 		$1.21M Buy
47,586
+90
+0.2% +$2.22K 0.17% 128
2019
Q1 		$1.24M Sell
47,496
-300
-0.6% -$7.37K 0.17% 127
2018
Q4 		$1.1M Buy
+47,796
New +$1.06M 0.18% 119

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Lowe Brockenbrough & Co's NVO Position: Q2 2026 in Review

Lowe Brockenbrough & Co held its Novo Nordisk (NVO) position steady in Q2 2026 at 26,886 shares worth $1.29M. The position accounts for 0.06% of the portfolio, ranked #168.

Lowe Brockenbrough & Co first reported a position in NVO in Q4 2018 and has held it in 30 quarters since. The position peaked at $4.75M in Q2 2024. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Lowe Brockenbrough & Co held 26,886 shares of Novo Nordisk worth $1.29M as of Q2 2026.
  • Lowe Brockenbrough & Co left its Novo Nordisk share count unchanged in Q2 2026.
  • Novo Nordisk made up 0.06% of Lowe Brockenbrough & Co's portfolio in Q2 2026, its #168 holding.
  • Lowe Brockenbrough & Co first reported a position in Novo Nordisk in Q4 2018 and has held it in 30 quarters since.
  • Lowe Brockenbrough & Co's Novo Nordisk position peaked at $4.75M in Q2 2024.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Lowe Brockenbrough & Co's 13F filing for Q2 2026, filed 3 Aug 2026.